JP2025532619A - イメージングおよび標的化放射線治療のための新規ミニガストリン由来コレシストキニン2受容体結合分子 - Google Patents

イメージングおよび標的化放射線治療のための新規ミニガストリン由来コレシストキニン2受容体結合分子

Info

Publication number
JP2025532619A
JP2025532619A JP2025515980A JP2025515980A JP2025532619A JP 2025532619 A JP2025532619 A JP 2025532619A JP 2025515980 A JP2025515980 A JP 2025515980A JP 2025515980 A JP2025515980 A JP 2025515980A JP 2025532619 A JP2025532619 A JP 2025532619A
Authority
JP
Japan
Prior art keywords
dota
glu
sifa
cck
trp
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2025515980A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025532619A5 (cg-RX-API-DMAC7.html
Inventor
ギュンター,トーマス
ホルツライトナー,ナディーヌ
ウェスター,ハンス・ユルゲン
ラパ,コンスタンタン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Augsburg
Original Assignee
University of Augsburg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Augsburg filed Critical University of Augsburg
Publication of JP2025532619A publication Critical patent/JP2025532619A/ja
Publication of JP2025532619A5 publication Critical patent/JP2025532619A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1024—Tetrapeptides with the first amino acid being heterocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/06—Macromolecular compounds, carriers being organic macromolecular compounds, i.e. organic oligomeric, polymeric, dendrimeric molecules
    • A61K51/065—Macromolecular compounds, carriers being organic macromolecular compounds, i.e. organic oligomeric, polymeric, dendrimeric molecules conjugates with carriers being macromolecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
JP2025515980A 2022-09-20 2023-05-19 イメージングおよび標的化放射線治療のための新規ミニガストリン由来コレシストキニン2受容体結合分子 Pending JP2025532619A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP22196630 2022-09-20
EP22196630.2 2022-09-20
PCT/EP2023/063469 WO2024061483A1 (en) 2022-09-20 2023-05-19 Novel minigastrin-derived cholecystokinin 2 receptor binding molecules for imaging and targeted radiotherapy

Publications (2)

Publication Number Publication Date
JP2025532619A true JP2025532619A (ja) 2025-10-01
JP2025532619A5 JP2025532619A5 (cg-RX-API-DMAC7.html) 2025-12-16

Family

ID=83994946

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2025515980A Pending JP2025532619A (ja) 2022-09-20 2023-05-19 イメージングおよび標的化放射線治療のための新規ミニガストリン由来コレシストキニン2受容体結合分子

Country Status (9)

Country Link
EP (2) EP4590347A1 (cg-RX-API-DMAC7.html)
JP (1) JP2025532619A (cg-RX-API-DMAC7.html)
KR (1) KR20250073200A (cg-RX-API-DMAC7.html)
CN (1) CN119907695A (cg-RX-API-DMAC7.html)
AU (1) AU2023345654A1 (cg-RX-API-DMAC7.html)
CA (1) CA3264385A1 (cg-RX-API-DMAC7.html)
IL (1) IL319379A (cg-RX-API-DMAC7.html)
MX (1) MX2025003151A (cg-RX-API-DMAC7.html)
WO (1) WO2024061483A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12642876B1 (en) 2025-10-30 2026-06-02 Perspective Therapeutics, Inc. Cholecystokinin-2 receptor targeted compounds and use thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3412303A1 (en) * 2017-06-08 2018-12-12 Medizinische Universität Innsbruck Improved pharmacokinetics and cholecystokinin-2 receptor (cck2r) targeting for diagnosis and therapy
KR20240027896A (ko) * 2017-07-28 2024-03-04 테크니쉐 우니베르지테트 뮌헨 이중 모드 방사성 트레이서 및 치료법
EP4023250A1 (en) * 2021-01-04 2022-07-06 Technische Universität München Dual mode radiotracer and -therapeutics

Also Published As

Publication number Publication date
KR20250073200A (ko) 2025-05-27
CA3264385A1 (en) 2024-03-28
CN119907695A (zh) 2025-04-29
AU2023345654A1 (en) 2025-02-27
WO2024061483A1 (en) 2024-03-28
MX2025003151A (es) 2025-04-02
EP4590347A1 (en) 2025-07-30
IL319379A (en) 2025-05-01
EP4631959A3 (en) 2025-12-17
EP4631959A2 (en) 2025-10-15

Similar Documents

Publication Publication Date Title
CN111132700B (zh) 双模放射性示踪剂与治疗剂
CN113677400B (zh) 结合psma的双模式放射性示踪剂及治疗剂
JP2025011169A (ja) 画像化および内部放射線療法のためのpsmaリガンド
Failla et al. Peptide-based positron emission tomography probes: current strategies for synthesis and radiolabelling
KR20200009091A (ko) 신규 psma-결합제 및 이의 용도
KR20130132935A (ko) Nota에 의해 복합체를 형성한 알루미늄―〔18〕플루오라이드로 표지된 her2 결합 펩티드
KR20130132939A (ko) 18f - 함유 유기실리콘 화합물로 표지된 her2 결합 펩티드
JP7838149B2 (ja) 癌のイメージングおよび治療のための修飾されたgrprアンタゴニストペプチド
AU2022219294A1 (en) Cxcr4-ligands for diagnostic and therapeutic use and precursors thereof
EP4631959A2 (en) Novel minigastrin-derived cholecystokinin 2 receptor binding molecules for imaging and targeted radiotherapy
JP2024531844A (ja) 架橋基としてキレート化基を含むリガンド化合物
JP2024517971A (ja) 放射性医薬品のソマトスタチン受容体リガンドおよびその前駆体
JP2025525111A (ja) 放射性医薬品のためのケイ素系フッ化物アクセプター基
WO2025171887A1 (en) Radiolabeled complexes and pharmaceutical compositions including the same
CN120239618A (zh) 放射性标记的psma配体化合物及其前体
WO2025162868A1 (en) Compounds comprising a silicon-based fluoride acceptor group useful as radiopharmceutical compounds

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251208

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20251208